Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.46 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.46 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.46 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15359822 | 0.83 | HDAC6 (0.57) | ALDH1A1MAPTPRKAG1PRKAA2PRKAB1 | |
| SCHEMBL16040266 | 0.81 | ALDH1A1 (0.60) | ALDH1A1MAPTPRKAG1PRKAA2PRKAB1 | |
| SCHEMBL14833994 | 0.78 | HDAC6 (0.62) | ALDH1A1MAPTGMNNLMNACYP2D6 | |
| SCHEMBL15442916 | 0.77 | MAPT (0.51) | ALDH1A1MAPTKDM4ELMNACYP2D6 | |
| SCHEMBL2446345 | 0.73 | HPGD (0.48) | ALDH1A1MAPTPRKAG1PRKAA2PRKAB1 | |
| SCHEMBL12634224 | 0.73 | HDAC6 (0.46) | ALDH1A1MAPTKDM4EGMNNLMNA | |
| SCHEMBL2017763 | 0.72 | CHRM1 (0.82) | ALDH1A1MAPTCHRM1KDM4ECYP1A2 | |
| SCHEMBL28005156 | 0.71 | MAPT (0.62) | ALDH1A1MAPTPRKAG1PRKAA2PRKAB1 | |
| SCHEMBL19545527 | 0.71 | HDAC6 (0.62) | ALDH1A1MAPTGMNNLMNACYP2D6 | |
| SCHEMBL1920686 | 0.70 | ALDH1A1 (0.44) | ALDH1A1MAPTPRKAG1PRKAA2PRKAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020117257-A1 | COMBINATION THERAPY OF DIFFUSE LARGE B-CELL LYMPHOMA COMPRISING AN ANTI-CD79B IMMUNOCONJUGATES, AN ALKYLATING AGENT AND AN ANTI-CD20 ANTIBODY | GENENTECH, INC. (US) | 2020-06-11 | — | — | WO | claimed |
| EP-3262071-A1 | METHOD OF USING ANTI-CD79b IMMUNOCONJUGATES | F. Hoffmann-La Roche AG (CH) | 2018-01-03 | — | — | EP | claimed |
| WO-2016049214-A1 | METHOD OF USING ANTI-CD79b IMMUNOCONJUGATES | GENENTECH, INC. (US) | 2016-03-31 | — | — | WO | claimed |
| WO-2025085781-A1 | COMBINATIONS OF IL15/IL15R ALPHA HETERODIMERIC FC-FUSION PROTEINS AND HER2XCD3 BISPECIFIC ANTIBODIES FOR THE TREATMENT OF HER2-POSITIVE CANCERS | GENENTECH, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| EP-4441085-A2 | HIGH SELECTIVE CD229 ANTIGEN BINDING DOMAINS AND METHODS OF USE | University of Utah Research Foundation (US) | 2024-10-09 | — | — | EP | disclosed |
| WO-2024102332-A1 | VACCINE COMPOSITIONS COMPRISING A NEOANTIGEN OF KRAS | HIMV LLC (US) | 2024-05-16 | — | — | WO | disclosed |
| WO-2024091826-A1 | LYOPHILIZED BENDAMUSTINE-CYCLODEXTRIN COMPOSITION | SOFTKEMO PHARMA INC. (CA) | 2024-05-02 | — | — | WO | disclosed |
| EP-4243857-A1 | COMBINATION THERAPIES WITH CHIMERIC ANTIGEN RECEPTOR (CAR)-EXPRESSING CELLS | Novartis AG (CH) | 2023-09-20 | — | — | EP | disclosed |
| WO-2023102201-A2 | HIGH SELECTIVE CD229 ANTIGEN BINDING DOMAINS AND METHODS OF USE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023044483-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HER2 POSITIVE CANCER | VOYAGER THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| US-11466094-B2 | Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies | GENENTECH, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| EP-2793892-A1 | COMBINATION THERAPIES FOR TREATING HEMATOLOGIC MALIGNANCIES USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K/MTOR WITH BENDAMUSTINE AND/OR RITUXIMAB | Exelixis, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| WO-2014127802-A1 | STABLE COMPOSITIONS OF BENDAMUSTINE | SYNTHON BV (NL) | 2014-08-28 | — | — | WO | disclosed |
| WO-2013171289-A1 | COMBINATION OF CD37 ANTIBODIES WITH FURTHER AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-21 | — | — | WO | disclosed |
| WO-2013150020-A1 | PROCESS FOR MAKING BENDAMUSTINE | SYNTHON BV (NL) | 2013-10-10 | — | — | WO | disclosed |
| EP-2595660-A2 | BENDAMUSTINE ANIONIC-CATIOINIC CYCLOPOLYSACCHARIDE COMPOSITIONS | Supratek Pharma, Inc. (CA) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012174327-A1 | COMBINATION THERAPIES FOR TREATING HEMATOLOGIC MALIGNANCIES USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K/MTOR WITH BENDAMUSTINE AND/OR RITUXIMAB | EXELIXIS, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012127277-A2 | BENDAMUSTINE ANIONIC-CATIOINIC CYCLOPOLYSACCHARIDE COMPOSITIONS | SUPRATEK PHARMA, INC. (CA) | 2012-09-27 | — | — | WO | disclosed |
| EP-2326306-A1 | LIQUID FORMULATIONS OF BENDAMUSTINE | Cephalon, Inc. (US) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010036702-A1 | LIQUID FORMULATIONS OF BENDAMUSTINE | CEPHALON, INC. (US) | 2010-04-01 | — | — | WO | disclosed |